Ocular Therapeutix (OCUL) Prices 3.725M Share Common Offering at $21.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- S&P 500, Nasdaq eye tepid open as Middle East tensions weigh
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Pre-Open Stock Movers 12/15: (PRVL) (OCX) (MDWD) Higher; (MIRM) (SNOW) (OCUL) Lower (more...)
December 15, 2020 9:12 AM ESTToday's Pre-Open Stock Movers
Prevail Therapeutics Inc. (NASDAQ: PRVL) 84.6% HIGHER; Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash... More
After-Hours Stock Movers 12/14: (MDWD) (ARVN) (IVAC) Higher; (OCUL) (EAF) (ZIOP) Lower (more...)
December 14, 2020 5:24 PM ESTToday's After-Hours Stock Movers
MediWound Ltd. (Nasdaq: MDWD) 25% HIGHER; announced it has further expanded its NexoBrid® global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval,... More
Ocular Therapeutix (OCUL) Announces $75M Proposed Public Offering of Common Stock
December 14, 2020 4:13 PM ESTOcular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of $75.0 million of its common stock. In... More
